Observational study of men with advanced prostate cancer
Longitudinal Advanced Prostate Cancer Cohort (LAPCC)
University of Southern California · NCT06067295
This study is collecting blood, urine, and health information from men with advanced prostate cancer to help researchers learn more about the disease and improve future treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | University of Southern California (other) |
| Locations | 2 sites (Los Angeles, California and 1 other locations) |
| Trial ID | NCT06067295 on ClinicalTrials.gov |
What this trial studies
This study collects biological samples and health information from men diagnosed with advanced prostate cancer to better understand the disease and improve future treatment outcomes. Participants will provide blood and urine samples, complete surveys, and have their medical records reviewed. The primary goal is to create a biorepository that can be used for further research into prostate cancer. This observational approach allows researchers to gather real-world data on treatment responses and quality of life.
Who should consider this trial
Good fit: Ideal candidates are men aged 18 and older with a diagnosis of advanced prostate cancer who are about to start a new systemic treatment.
Not a fit: Patients who are unable to give informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and outcomes for patients with advanced prostate cancer.
How similar studies have performed: Other observational studies have successfully contributed to understanding advanced prostate cancer, making this approach both relevant and valuable.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men of all racial and ethnic groups 18 years of age or older * Men with a diagnosis of advanced (metastatic) prostate cancer who are scheduled to begin a new systemic treatment (including first or subsequent lines of therapy) * Prior participation on clinical trials is allowed Exclusion Criteria: * Inability to give informed consent * Any other malignancy, unless previously treated with curative intent and the subject has been disease free for 3 years or longer
Where this trial is running
Los Angeles, California and 1 other locations
- Los Angeles General Medical Center — Los Angeles, California, United States (RECRUITING)
- USC / Norris Comprehensive Cancer Center — Los Angeles, California, United States (RECRUITING)
Study contacts
- Principal investigator: Amir Goldkorn, MD — University of Southern California
- Study coordinator: Cheryl Kefauver, RN
- Email: Cheryl.Kefauver@med.usc.edu
- Phone: 323-865-0459
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Prostate Carcinoma